Axim taps CRO for cannabinoid product development and clinical trials

By Melissa Fassbender

- Last updated on GMT

Axim taps CRO for cannabinoid product development

Related tags Contract research organization

Axim Biotech has contracted an ophthalmology CRO to support upcoming product development and clinical trials for its cannabinoid-based therapeutics.

Axim Biotechnologies’ flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum.

Canchew CBD gum. (Image: Axim Biotech)
Canchew CBD gum. (Image: Axim Biotech)

As previously reported​, the company has enrolled 40 patients for its Canchew Plus chewing gum Ph II clinical trial.

Now, the company contracted Ora, Inc., a global contract research organization (CRO) to help advance its AX-1603 and AX-1606 clinical programs.

George E. Anastassov, MD, DDS, and CEO of AXIM Biotech, told us the contract research organization (CRO) will provide product development based on Axim’s filed intellectual property (IP).

Within the next eight weeks Ora will develop a plan of action for two trials​,” said Anastossov. The Ph II clinical trials will examine the ability of cannabinoids to treat glaucoma and dry eye syndrome.

Axim is extremely excited to begin the program​,” Anastossov added.

The program will be run under the supervision of Prof. Robert Ritch, an Axim advisory board member and Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE).

(Feature image: iStock/petdcat)

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars